Merck KGaA, New Biological Entities Drug Metabolism & Pharmacokinetics, Darmstadt, 64293, Germany.
Nuvisan GmbH, Bioanalysis, Neu-Ulm, 89231, Germany.
Bioanalysis. 2022 Jul;14(13):911-917. doi: 10.4155/bio-2022-0143. Epub 2022 Jul 29.
Since 2011, the European Bioanalysis Forum has been discussing the topic of context-of-use for biomarker assays, in support of a cross-industry implementation of its principles. The discussions have led to the acknowledgement of the challenges that we face as an industry in implementing these principles. In addition to scientific recommendations, the European Bioanalysis Forum has addressed these challenges by providing recommendations on organizational design, and what works in both sponsor and contract research organizations, to support and enable context-of-use across biomarker strategies. Here, we highlight the key considerations for organizational design to help ensure that biomarker assays are characterized and validated according to the right context-of-use, to ensure that the right decisions based on the biomarker data can be made during drug development.
自 2011 年以来,欧洲生物分析论坛一直在讨论生物标志物检测的实际应用背景这一主题,以支持其原则在整个行业内的实施。这些讨论使人们认识到我们在实施这些原则方面所面临的挑战。除了科学建议外,欧洲生物分析论坛还通过提供有关组织设计的建议,以及在赞助商和合同研究组织中可行的建议,来支持和实现生物标志物策略的实际应用背景,从而应对这些挑战。在这里,我们重点介绍组织设计的关键注意事项,以帮助确保根据正确的实际应用背景来描述和验证生物标志物检测,以确保在药物开发过程中可以根据生物标志物数据做出正确的决策。